Eli Lilly and Company LLY
NYSE
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 49.79% | 93.55% | 127.59% | 94.90% | 119.98% |
| Total Depreciation and Amortization | 14.63% | 10.87% | 11.66% | 13.00% | 13.58% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 169.71% | 31.13% | -113.22% | 23.00% | 3.08% |
| Change in Net Operating Assets | 16.10% | 38.94% | 8.63% | -50.32% | -4.91% |
| Cash from Operations | 90.79% | 156.72% | 119.79% | 90.66% | 166.27% |
| Capital Expenditure | -61.76% | -63.41% | -55.09% | -55.02% | -46.58% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -1,866.79% | -3,488,433.33% | -81.29% | 30.32% | 72.42% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -213.61% | 6.34% | 76.58% | 25.06% | 25.28% |
| Cash from Investing | -201.42% | -125.83% | -0.49% | -17.94% | 2.09% |
| Total Debt Issued | -32.10% | 83.19% | -25.77% | 15.33% | -17.77% |
| Total Debt Repaid | 21.72% | -433.59% | -578.36% | -103.35% | 62.69% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -25.52% | -40.54% | -42.26% | -64.31% | -943.24% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -14.86% | -14.99% | -15.02% | -15.05% | -14.94% |
| Other Financing Activities | 19.55% | 19.88% | 14.11% | -57.05% | -66.12% |
| Cash from Financing | -1,267.26% | 2,059.11% | -341.77% | -279.90% | -91.19% |
| Foreign Exchange rate Adjustments | -61.76% | -109.80% | 336.99% | 225.22% | -96.09% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -176.39% | 3,567.43% | 246.22% | 790.98% | 549.93% |